IRADIMED CORP (IRMD) Stock Fundamental Analysis
USA - NASDAQ:IRMD - US46266A1097 - Common Stock
71.46 USD
-0.15 (-0.21%)
71.46 USD
0 (0%)
Overall IRMD gets a fundamental rating of 7 out of 10. We evaluated IRMD against 191 industry peers in the Health Care Equipment & Supplies industry. IRMD scores excellent points on both the profitability and health parts. This is a solid base for a good stock. IRMD has a correct valuation and a medium growth rate. This makes IRMD very considerable for quality investing!
1. Profitability
1.1 Basic Checks
In the past year IRMD was profitable.
In the past year IRMD had a positive cash flow from operations.
IRMD had positive earnings in each of the past 5 years.
In the past 5 years IRMD always reported a positive cash flow from operatings.
1.2 Ratios
IRMD has a better Return On Assets (19.41%) than 97.91% of its industry peers.
IRMD has a Return On Equity of 21.91%. This is amongst the best in the industry. IRMD outperforms 93.72% of its industry peers.
IRMD's Return On Invested Capital of 19.30% is amongst the best of the industry. IRMD outperforms 97.38% of its industry peers.
The Average Return On Invested Capital over the past 3 years for IRMD is significantly above the industry average of 8.46%.
The last Return On Invested Capital (19.30%) for IRMD is above the 3 year average (18.78%), which is a sign of increasing profitability.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 19.41% | ||
| ROE | 21.91% | ||
| ROIC | 19.3% |
ROA(3y)17.74%
ROA(5y)13.28%
ROE(3y)21.21%
ROE(5y)15.76%
ROIC(3y)18.78%
ROIC(5y)N/A
1.3 Margins
Looking at the Profit Margin, with a value of 26.61%, IRMD belongs to the top of the industry, outperforming 94.76% of the companies in the same industry.
In the last couple of years the Profit Margin of IRMD has remained more or less at the same level.
Looking at the Operating Margin, with a value of 30.67%, IRMD belongs to the top of the industry, outperforming 97.38% of the companies in the same industry.
In the last couple of years the Operating Margin of IRMD has grown nicely.
IRMD has a better Gross Margin (76.96%) than 89.53% of its industry peers.
IRMD's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 30.67% | ||
| PM (TTM) | 26.61% | ||
| GM | 76.96% |
OM growth 3Y8.49%
OM growth 5Y5.96%
PM growth 3Y5.58%
PM growth 5Y0.99%
GM growth 3Y0.12%
GM growth 5Y-0.04%
2. Health
2.1 Basic Checks
IRMD has a Return on Invested Capital (ROIC), which is well above the Cost of Capital (WACC), which means it is creating value.
The number of shares outstanding for IRMD has been increased compared to 1 year ago.
Compared to 5 years ago, IRMD has more shares outstanding
There is no outstanding debt for IRMD. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
An Altman-Z score of 47.97 indicates that IRMD is not in any danger for bankruptcy at the moment.
IRMD's Altman-Z score of 47.97 is amongst the best of the industry. IRMD outperforms 100.00% of its industry peers.
IRMD has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Altman-Z | 47.97 |
ROIC/WACC2.22
WACC8.69%
2.3 Liquidity
IRMD has a Current Ratio of 8.78. This indicates that IRMD is financially healthy and has no problem in meeting its short term obligations.
The Current ratio of IRMD (8.78) is better than 90.05% of its industry peers.
A Quick Ratio of 7.51 indicates that IRMD has no problem at all paying its short term obligations.
The Quick ratio of IRMD (7.51) is better than 90.05% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 8.78 | ||
| Quick Ratio | 7.51 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an nice 11.25% over the past year.
IRMD shows quite a strong growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 13.92% yearly.
IRMD shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 11.74%.
The Revenue has been growing by 13.71% on average over the past years. This is quite good.
EPS 1Y (TTM)11.25%
EPS 3Y25.74%
EPS 5Y13.92%
EPS Q2Q%16.67%
Revenue 1Y (TTM)11.74%
Revenue growth 3Y20.55%
Revenue growth 5Y13.71%
Sales Q2Q%13.84%
3.2 Future
IRMD is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 12.71% yearly.
IRMD is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 11.12% yearly.
EPS Next Y14.36%
EPS Next 2Y12.71%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year11.87%
Revenue Next 2Y11.12%
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.
The Revenue growth rate is stable: in the next years the growth will be about the same than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
Based on the Price/Earnings ratio of 40.15, the valuation of IRMD can be described as expensive.
70.16% of the companies in the same industry are more expensive than IRMD, based on the Price/Earnings ratio.
IRMD is valuated rather expensively when we compare the Price/Earnings ratio to 27.20, which is the current average of the S&P500 Index.
The Price/Forward Earnings ratio is 34.09, which means the current valuation is very expensive for IRMD.
71.73% of the companies in the same industry are more expensive than IRMD, based on the Price/Forward Earnings ratio.
When comparing the Price/Forward Earnings ratio of IRMD to the average of the S&P500 Index (22.71), we can say IRMD is valued expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 40.15 | ||
| Fwd PE | 34.09 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, IRMD is valued a bit cheaper than 70.68% of the companies in the same industry.
Based on the Price/Free Cash Flow ratio, IRMD is valued a bit cheaper than the industry average as 72.77% of the companies are valued more expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 68.18 | ||
| EV/EBITDA | 34.79 |
4.3 Compensation for Growth
The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
IRMD has an outstanding profitability rating, which may justify a higher PE ratio.
A more expensive valuation may be justified as IRMD's earnings are expected to grow with 12.71% in the coming years.
PEG (NY)2.79
PEG (5Y)2.88
EPS Next 2Y12.71%
EPS Next 3YN/A
5. Dividend
5.1 Amount
With a yearly dividend of 0.89%, IRMD is not a good candidate for dividend investing.
Compared to an average industry Dividend Yield of 1.69, IRMD pays a better dividend. On top of this IRMD pays more dividend than 93.19% of the companies listed in the same industry.
Compared to an average S&P500 Dividend Yield of 2.38, IRMD's dividend is way lower than the S&P500 average.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0.89% |
5.2 History
IRMD has been paying a dividend for less than 5 years, so it still needs to build a track record.
Dividend Growth(5Y)N/A
Div Incr Years0
Div Non Decr Years0
5.3 Sustainability
39.33% of the earnings are spent on dividend by IRMD. This is a low number and sustainable payout ratio.
DP39.33%
EPS Next 2Y12.71%
EPS Next 3YN/A
71.46
-0.15 (-0.21%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)
Earnings (Next)
Inst Owners58.46%
Inst Owner Change1.21%
Ins Owners36.83%
Ins Owner Change0.67%
Market Cap908.97M
Analysts82.5
Price Target74.97 (4.91%)
Short Float %1.89%
Short Ratio3.15
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0.89% |
Yearly Dividend1.08
Dividend Growth(5Y)N/A
DP39.33%
Div Incr Years0
Div Non Decr Years0
Ex-Date
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)5.43%
Min EPS beat(2)0.43%
Max EPS beat(2)10.44%
EPS beat(4)3
Avg EPS beat(4)4.6%
Min EPS beat(4)-1.96%
Max EPS beat(4)10.44%
EPS beat(8)6
Avg EPS beat(8)6.12%
EPS beat(12)10
Avg EPS beat(12)7.27%
EPS beat(16)14
Avg EPS beat(16)11.73%
Revenue beat(2)1
Avg Revenue beat(2)-0.52%
Min Revenue beat(2)-1.05%
Max Revenue beat(2)0.01%
Revenue beat(4)1
Avg Revenue beat(4)-0.62%
Min Revenue beat(4)-1.05%
Max Revenue beat(4)0.01%
Revenue beat(8)3
Avg Revenue beat(8)-0.43%
Revenue beat(12)5
Avg Revenue beat(12)-0.16%
Revenue beat(16)7
Avg Revenue beat(16)-0.07%
PT rev (1m)0%
PT rev (3m)3.52%
EPS NQ rev (1m)0%
EPS NQ rev (3m)5.75%
EPS NY rev (1m)6.63%
EPS NY rev (3m)6.63%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)3.77%
Revenue NY rev (1m)2.84%
Revenue NY rev (3m)2.84%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 40.15 | ||
| Fwd PE | 34.09 | ||
| P/S | 11.71 | ||
| P/FCF | 68.18 | ||
| P/OCF | 33.49 | ||
| P/B | 9.64 | ||
| P/tB | 10 | ||
| EV/EBITDA | 34.79 |
EPS(TTM)1.78
EY2.49%
EPS(NY)2.1
Fwd EY2.93%
FCF(TTM)1.05
FCFY1.47%
OCF(TTM)2.13
OCFY2.99%
SpS6.1
BVpS7.41
TBVpS7.15
PEG (NY)2.79
PEG (5Y)2.88
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 19.41% | ||
| ROE | 21.91% | ||
| ROCE | 24.39% | ||
| ROIC | 19.3% | ||
| ROICexc | 42.22% | ||
| ROICexgc | 45.68% | ||
| OM | 30.67% | ||
| PM (TTM) | 26.61% | ||
| GM | 76.96% | ||
| FCFM | 17.17% |
ROA(3y)17.74%
ROA(5y)13.28%
ROE(3y)21.21%
ROE(5y)15.76%
ROIC(3y)18.78%
ROIC(5y)N/A
ROICexc(3y)57.41%
ROICexc(5y)N/A
ROICexgc(3y)63.62%
ROICexgc(5y)N/A
ROCE(3y)23.73%
ROCE(5y)N/A
ROICexcg growth 3Y-6.9%
ROICexcg growth 5Y0.27%
ROICexc growth 3Y-6.89%
ROICexc growth 5Y-0.24%
OM growth 3Y8.49%
OM growth 5Y5.96%
PM growth 3Y5.58%
PM growth 5Y0.99%
GM growth 3Y0.12%
GM growth 5Y-0.04%
F-Score4
Asset Turnover0.73
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Debt/EBITDA | 0 | ||
| Cap/Depr | 1738.97% | ||
| Cap/Sales | 17.79% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 110.32% | ||
| Profit Quality | 64.54% | ||
| Current Ratio | 8.78 | ||
| Quick Ratio | 7.51 | ||
| Altman-Z | 47.97 |
F-Score4
WACC8.69%
ROIC/WACC2.22
Cap/Depr(3y)801.75%
Cap/Depr(5y)501.1%
Cap/Sales(3y)9.26%
Cap/Sales(5y)6.31%
Profit Quality(3y)60.91%
Profit Quality(5y)134.72%
High Growth Momentum
Growth
EPS 1Y (TTM)11.25%
EPS 3Y25.74%
EPS 5Y13.92%
EPS Q2Q%16.67%
EPS Next Y14.36%
EPS Next 2Y12.71%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)11.74%
Revenue growth 3Y20.55%
Revenue growth 5Y13.71%
Sales Q2Q%13.84%
Revenue Next Year11.87%
Revenue Next 2Y11.12%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y11.02%
EBIT growth 3Y30.78%
EBIT growth 5Y20.49%
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y86.2%
FCF growth 3Y16.9%
FCF growth 5Y11.53%
OCF growth 1Y79.39%
OCF growth 3Y31.53%
OCF growth 5Y20.16%